Axsome Therapeutics (AXSM – Research Report ... The potential regulatory approvals for AXS-07, AXS-14, and AXS-12 in the near to medium term, along with the expected submission of AXS-05 ...

Fintel reports that on February 11, 2025, Deutsche Bank initiated coverage of Axsome Therapeutics (NasdaqGM:AXSM) with a Buy ...

Axsome Therapeutics Background Information (This ... AXS-09, AXS-12, and AXS-14. AXS-05 is being developed for major depressive disorder (MDD), Alzheimer's disease (AD) agitation, and as a ...

17 analysts have expressed a variety of opinions on Axsome Therapeutics AXSM ... Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment ...

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical ... Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting ...

Axsome Therapeutics ... Analysts project that AXS-05 could generate over $500 million in AD agitation revenue five years post-launch, with a 14% peak penetration rate. The company is also ...

Axsome Therapeutics, Inc. (NASDAQ ... Analysts project that AXS-05 could generate over $500 million in AD agitation revenue five years post-launch, with a 14% peak penetration rate. The company is ...

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical ... Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, ...

Axsome's lead candidate, AXS-05, is currently in late-stage development for the treatment of Alzheimer's Disease Agitation (ADA). This condition affects approximately 70% of Alzheimer's patients and ...

Ratings for Axsome Therapeutics AXSM were provided ... Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit ...